Cancer BiologybioRxiv
An in vivo inflammatory loop potentiates KRAS blockade
K. A. Arendt, G. Ntaliarda, V. Armenis…·G. T. Stathopoulos
The paper shows that KRAS-mutant tumors rely on an inflammatory loop involving C-C-motif chemokine ligand 2/interleukin-1β signaling, making them resistant to KRAS inhibitors in vivo but responsive in certain transplant models.